bevacizumab
roche
[]
 so more benefit in the group which could have benefit from bev, however absent from the "physician's choice"... pervasive issue of "physician's choice" control arm 
Medicine, Oncology (sarcoma, H&N, CUP), Research = EBM, Epi, Policy #metaresearch @Hopitaux_unige (Geneva, CH), @vkprasadlab (UCSF). No COI. Views mine.